InsidersTradesSigma
基于 8 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the full record of transactions filed by Eldred Kary. Director active across 1 company, notably Galectin Therapeutics INC. In total, 12 disclosures have been published. Breakdown: 12 buys · 0 sell. Total volume traded: €27k. History available since 25 January 2023. The latest transaction was disclosed on 6 February 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 条申报中的 12 条
ELDRED KARY is a declarant linked to Galectin Therapeutics INC, where he is a Director. The 12 filings recorded, all within the sampled recent filings, cover the period from 2023-01-26 to 2026-02-09 and show acquisitions only, with total buys of EUR 27376 and no sells.